Introduction: Obesity is an independent risk factor for cardiovascular disease (CVD) as it increases inflammation and oxidative stress in the body. Glucagon Like Peptide-1 (GLP-1 RA) agonist receptors, such as semaglutide, reduce weight, improve blood sugar levels, and promote cardioprotection. GLP-1 Ras extend the life of GLP-1, an incretin responsible for processes that decrease hyperglycemia, leading to weight loss. Objective: To understand the cardioprotective effects of semaglutide in obese patients. Method: We conducted a literature review focusing on identifying the cardioprotective effects of semaglutide use in obese patients. Results and Discussion: The hyperglycemic and pro-inflammatory state of obese individuals favors pro-thrombotic mechanisms and cardiovascular dysfunction. GLP-1 Ras mediate their effects through the GLP-1 receptor, showing a reduced risk of CVD as they have beneficial effects on reducing blood pressure, weight, lipid levels, and glucose. Semaglutide acts as a long-acting GLP-1 RA, demonstrating a greater ability to reduce weight within this class, and works by stimulating insulin secretion by pancreatic beta cells and reduces glucagon production by alpha pancreatic cells. Conclusion: According to the literature, it is possible to consider that semaglutide promotes cardioprotection in obese patients. However, further studies are still needed to confirm this relationship and achieve greater efficacy in treatment.